Mechanisms Underlying SGLT2i Kidney Effect in DKD Progression

Inclusion Criteria (to be eligible to participate in this trial, an individual must meet all the following criteria): * male and female subjects aged ≥ 18 years; * written informed consent prior to any study specific procedures * type 2 Diabetes Mellitus with DKD * CKD stage 1 to 3 (eGFR\>30 ml/min) with moderate or severe risk of renal disease progression (according to KDIGO 2024 CKD guidelines, G1 and G2 with albuminuria \>300 mg/g, G3a with albuminuria \>30 mg/g, and G3b independently of albuminuria levels) * ongoing SGLT2i treatment (e.g. canagliflozin, empagliflozin or dapagliflozin) for at least 1 year and stable RAS inhibitor therapy with ACE inhibitors and/or ARBs (or without RAS inhibitors in patients with specific contraindications for this medication) Exclusion Criteria (an individual who meets any of the following criteria will be excluded from participation in this trial): * Uncontrolled diabetes (glycated hemoglobin (A1C) \> 8%; 64 mmol/mol) * Contraindications to MRI including claustrophobia, pregnancy or lactating, cardiac pacemakers, or other MRI-incompatible prostheses, or impossibility to perform MRI * Any chronic clinical condition (e.g. history of malignancy) other than CKD and related complications that could affect completion of the trial or confound data interpretation * Non-diabetic CKD: CKD highly suspected to be related with a different renal condition other than Diabetes Mellitus as the cause of CKD (i.e. glomerular disease, tubulo-interstitial …